|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.02 |
|
|
À̳뿡ÀÌÄ¡¾ËÄÁ¼³Æà |
[±¹³»À¯¸íÁ¦¾àȸ»ç] CRM(Clinical Research Manager) ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.15 |
|
|
¾Ë¸®ÄÚÁ¦¾à(ÁÖ) |
[°æ·Â] Á¦¾à»ç ÀÓ»ó ´ã´çÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
08.17 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
05.04 |
|
|
Á¦ÀÌ¿¥Æ¼(ÁÖ) |
ÀÇ·á±â±â(Ä«Å×ÅÍ) ¿¬±¸°³¹ß(¼³°è) °æ·ÂÁ÷ ¸ðÁý
°æ±â ¾çÁֽà | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
05.10 |
|
|
(ÁÖ)Çѱ¹ºñ¿¥¾ÆÀÌ |
¿¡½ºÅ×ƽ Á¦Ç° °³¹ß(ÇÊ·¯, Åå½Å)
°æ±â Àǿսà | Çз¹«°ü |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
10.13 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Moinitori & Lead Monito
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.21 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾àȸ»ç CRM
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.18 |
|
|
(ÁÖ)Å¥¶óƼ½º |
ÀÓ»óÀÎÇã°¡ÆÀ PV Á¤±ÔÁ÷ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
06.22 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.08 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ- Sr. RA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ)Ç»ÃÄÄÍ |
°³¹ßºÎ ÀÓ»óPM ¸ðÁý
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
01.29 |
|
|
ÁÖ½Äȸ»ç Å¥¶óƼ½º |
ÀÓ»ó°³¹ßÆÀ Á¤±ÔÁ÷ ä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
10.24 |
|
|
¾Ëº¸Á¨ÄÚ¸®¾Æ |
BD In-License Specialist ä¿ë
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
01.16 |
|
|
(ÁÖ)Á¨¹Ùµð |
¿¬±¸°³¹ß(¹ÙÀÌ·¯½º ¹× ÀçÁ¶ÇմܹéÁú ¿¬±¸°³¹ß) ÆÀÀå±Þ ä¿ë
Ãæ³² õ¾È½Ã | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
04.15 |
|